FR 104

Drug Profile

FR 104

Alternative Names: Anti CD28 monoclonal antibody - OSE Therapeutics; FR-104

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Effimune
  • Developer Biomedical Primate Research Center; Nantes University Hospital; OSE Immunotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD28 antigen inhibitors; Immunomodulators; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Transplant rejection
  • Preclinical Encephalomyelitis; Multiple sclerosis; Psoriasis; Uveitis

Most Recent Events

  • 26 Sep 2017 OSE Immunotherapeutics plans a phase II trial for Rheumatoid arthritis in late 2018
  • 05 Jul 2016 Janssen Biotech exercised the global option and license agreement for the development and commercialisation of FR 104
  • 31 May 2016 Effimune has merged with OSE Pharma to form OSE Immunotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top